Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S287577-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $39.90 | |
S287577-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $110.90 | |
S287577-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $166.90 | |
S287577-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $365.90 | |
S287577-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $658.90 |
Potent sepiapterin reductase (SPR) inhibitor; attenuates proliferation of CD4+ T cells
Synonyms | SPR inhibitor 3;SPRi3 |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | Potent sepiapterin reductase (SPR) inhibitor (IC50= 53 - 74 nM for human SPR). Inhibits BH4 synthesis pathway and attenuates proliferation in naive CD4+T cells. Suppresses proliferation of human effector CD4+T cells following stimulation. Reduces SPR acti |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of sepiapterin reductase |
Product Description |
SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC50=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC50=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels.
|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | N-[2-(5-hydroxy-2-methyl-1H-indol-3-yl)ethyl]-2-methoxyacetamide |
---|---|
INCHI | InChI=1S/C14H18N2O3/c1-9-11(5-6-15-14(18)8-19-2)12-7-10(17)3-4-13(12)16-9/h3-4,7,16-17H,5-6,8H2,1-2H3,(H,15,18) |
InChi Key | YBXBWBBVLXZQBJ-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C2=C(N1)C=CC(=C2)O)CCNC(=O)COC |
Isomeric SMILES | CC1=C(C2=C(N1)C=CC(=C2)O)CCNC(=O)COC |
PubChem CID | 52911386 |
Molecular Weight | 262.30 |
Enter Lot Number to search for COA:
Solubility | Solvent:DMSO, Max Conc. mg/mL: 26.23, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 26.23, Max Conc. mM: 100 |
---|
1. Latremoliere A, Latini A, Andrews N, Cronin SJ, Fujita M, Gorska K, Hovius R, Romero C, Chuaiphichai S, Painter M et al.. (2015) Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway.. Neuron, 86 (6): (1393-406). [PMID:26087165] [10.1021/op500134e] |
2. Haruki H, Hovius R, Pedersen MG, Johnsson K. (2016) Tetrahydrobiopterin Biosynthesis as a Potential Target of the Kynurenine Pathway Metabolite Xanthurenic Acid.. J Biol Chem, 291 (2): (652-7). [PMID:26565027] [10.1021/op500134e] |